Skip to content

Serotonin: all studies

Page 323 of 401: studies 3,221 to 3,230 of 4,006, newest first. Back to the serotonin overview

Research

Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Noro psikiyatri arsivi March 2017 Berker Duman, Nilay Sedes, Bora Baskak

Methylenedioxymethamphetamine (MDMA) is an amphetamine-derived psychostimulant, usually known as "ecstasy." The long-term neuropsychological effects of MDMA are examined in several studies with conflicting results. The most common findings reported are depression, anxiety, and memory and attention deficits. In addition to acute psychotic reactions observed after MDMA use, serotonergic and...

DOI: 10.5152/npa.2017.16964 (opens in new tab) Full text (opens in new tab) Psychotic disorders Substance-induced psychosis Substance-related disorders

The fibrinolytic system: A new target for treatment of depression with psychedelics.

Medical Hypotheses March 2017 R D Idell, G Florova, A A Komissarov et al.

Current understanding of the neurobiology of depression has grown over the past few years beyond the traditional monoamine theory of depression to include chronic stress, inflammation and disrupted synaptic plasticity. Tissue plasminogen activator (tPA) is a key factor that not only promotes fibrinolysis via the activation of plasminogen, but also contributes to regulation of synaptic...

Disrupted integration of sensory stimuli with information about the movement of the body as a mechanism explaining LSD-induced experience.

Medical Hypotheses March 1, 2017 Grzegorz R Juszczak 4 citations

LSD (lysergic acid diethylamide) is a model psychedelic drug used to study mechanism underlying the effects induced by hallucinogens. However, despite advanced knowledge about molecular mechanism responsible for the effects induced by LSD and other related substances acting at serotonergic 5-HT2a receptors, we still do not understand how these drugs trigger specific sensory experiences....

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies

Therapeutic Advances in Psychopharmacology February 23, 2017 Rafael G. Dos Santos, José Carlos Bouso, Jaime E. C. Hallak 167 citations

Ayahuasca is a hallucinogen brew traditionally used for ritual and therapeutic purposes in Northwestern Amazon. It is rich in the tryptamine hallucinogens dimethyltryptamine (DMT), which acts as a serotonin 5-HT 2A agonist. This mechanism of action is similar to other compounds such as lysergic acid diethylamide (LSD) and psilocybin. The controlled use of LSD and psilocybin in experimental...

Psychiatric aspects of designer drugs and new psychoactive substances consumption

Interactive science February 22, 2017 Vladimir Valerievich Mrykhin, Andrey Viktorovich Antsyborov 2 citations

According to the authors, appeared not long ago new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, agonists of GABA (A/B) receptors have become a serious problem for both consumers and doctors. Consumers of these substances are attracted...

DOI: 10.21661/r-116849 (opens in new tab) Full text (opens in new tab) Designer drug Psychoactive substance Consumption sociology Mephedrone +1

Altered Insula Connectivity under MDMA.

Neuropsychopharmacology February 14, 2017 Ishan C Walpola, Timothy Nest, Leor Roseman et al. 50 citations

Recent work with noninvasive human brain imaging has started to investigate the effects of 3,4-methylenedioxymethamphetamine (MDMA) on large-scale patterns of brain activity. MDMA, a potent monoamine-releaser with particularly pronounced serotonin- releasing properties, has unique subjective effects that include: marked positive mood, pleasant/unusual bodily sensations and pro-social, empathic...

DOI: 10.1038/npp.2017.35 (opens in new tab) Full text (opens in new tab) MDMA Research MDMA Studies Ecstasy research Psychedelic research +24

Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N,N-dimethyltryptamine

bioRxiv (Cold Spring Harbor Laboratory) February 13, 2017 Vanja Dakic, Juliana Nascimento, Rafaela Sartore et al. preprint

Abstract Dimethyltryptamines are hallucinogenic serotonin-like molecules present in traditional Amerindian medicine (e.g. Ayahuasca) recently associated with cognitive gains, antidepressant effects and changes in brain areas related to attention. Historical and technical restrictions impaired understanding how such substances impact human brain metabolism. Here we used shotgun mass spectrometry...

DOI: 10.1101/108159 (opens in new tab) Full text (opens in new tab) Proteome Organoid Human brain Hallucinogen +6

Behavioral Patterns of Psychiatric Patients Using Synthetic Cannabinoids

Journal of Addiction Research February 7, 2017

Synthetic cannabinoids (SC) are analogs of natural cannabinoids that are chemically synthesized. These compounds are used frequently in the community as illicit substances. Literature review indicates that its use is increasing due to its easy accessibility despite it being placed under Schedule I of the Synthetic Drug Abuse Prevention Act of 2012. SC is readily found in most inner urban...

Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms

Chronic Stress February 1, 2017 Brendan Hare, Sriparna Ghosal, Ronald S. Duman 69 citations

Stress-associated disorders, including depression and anxiety, impact nearly 20% of individuals in the United States. The social, health, and economic burden imposed by stress-associated disorders requires in depth research efforts to identify suitable treatment strategies. Traditional medications (e.g., selective serotonin reuptake inhibitors, monoamine oxidase inhibitors) have significant...

DOI: 10.1177/2470547017697317 (opens in new tab) Anxiety Antidepressant Monoamine oxidase Prefrontal cortex +7